Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Decibel Therapeutics announces study on noise-related inner ear damage

By Brian Buntz | September 30, 2021

Decibel TherapeuticsDecibel Therapeutics (NSDQ:DBTX) has a working hypothesis that molecular characterization of the cell biology of the inner ear could pave the way for treatments for hearing and balance disorders. 

The Boston-based biotech company has announced that a recent study published in Cell Reports supports that hypothesis. 

“We were thrilled to leverage our data and expertise in inner ear biology to help fuel this analysis, which may help enable identification of therapeutics that counter the observed trends in gene expression that occur following noise exposure,” said Joe Burns, vice president, discovery at Decibel Therapeutics, in a statement. 

The company partnered with the University of Maryland School of Medicine and the Karolinska Institute on the research.

Decibel Therapeutics had its IPO on February 12. Its shares have since fallen from $18.03 apiece to $7.71 today.

Other hearing-loss-focused pharmaceutical forms have also see wide declines.

For instance, Otonomy (NSDQ:OTIC) has had its shares fall from $39.36 on March 13, 2015 to $1.92 today.

Similarly, Lexington, Massachusetts–based Frequency Therapeutics has also seen its stock plunge from $55.01 on February 19 to $7.06 today. 

On March 23, Frequency Therapeutics (NSDQ:FREQ) announced that interim results indicated that its lead pipeline candidate FX-322 was ineffective at improving mild to moderately severe sensorineural hearing loss in a Phase 2a study compared to placebo. Earlier that month, the company said the drug seemed to lead to hearing improvements in adults with age-related hearing loss. 

Frequency Therapeutics recently announced that several subjects receiving FX-322 in a small open-label study showed statistically significant hearing improvement eight to 12 months after initial dosing. 


Filed Under: ENT drugs
Tagged With: Cell Reports, Decibel Therapeutics, Frequency Therapeutics, FX-322, Otonomy
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Frequency Therapeutics
Frequency Therapeutics shares plummet after FX-322 Phase 2b failure
Otonomy
Otonomy gives up on experimental tinnitus drug after disappointing Phase 2 trial
Pfizer
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Decibel Therapeutics
Decibel Therapeutics touts progress with lead gene therapy product candidate DB-OTO
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE